Donate Help Contact The AHA Sign In Home
American Heart Association
Hypertension
Search: search_blue_button Advanced Search
Published Online
on February 4, 2008

Hypertension. 2008
Published online before print February 4, 2008, doi: 10.1161/HYPERTENSIONAHA.107.100693
A more recent version of this article appeared on March 1, 2008
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
51/3/712    most recent
HYPERTENSIONAHA.107.100693v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Der Sarkissian, S.
Right arrow Articles by Raizada, M. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Der Sarkissian, S.
Right arrow Articles by Raizada, M. K.
Related Collections
Right arrow ACE/Angiotension receptors
Right arrow Physiological and pathological control of gene expression
Right arrow Gene therapy

Submitted on August 29, 2007
Revised on September 21, 2007

Cardiac Overexpression of Angiotensin Converting Enzyme 2 Protects the Heart From Ischemia-Induced Pathophysiology

Shant Der Sarkissian; Justin L. Grobe; Lihui Yuan; Dhruv R. Narielwala; Glenn A. Walter; Michael J. Katovich; and Mohan K. Raizada*

From the Department of Physiology and Functional Genomics (S.D.S., L.Y., D.R.N., G.A.W., M.K.R.), College of Medicine, and Department of Pharmacodynamics (J.L.G., M.J.K.), College of Pharmacy, University of Florida, Gainesville.

* To whom correspondence should be addressed. E-mail: mraizada{at}phys.med.ufl.edu.

Abstract—Angiotensin converting enzyme 2 (ACE2) has been linked to cardiac dysfunction and hypertension-induced cardiac pathophysiology. In this study, we used a gene overexpression approach to investigate the role of ACE2 in cardiac function and remodeling after myocardial infarction. Rats received an intracardiac injection of 4.5x108 lentivirus containing ACE2 cDNA, followed by permanent coronary artery ligation (CAL) of the left anterior descending artery. At 24 hours and 6 weeks after surgery, cardiac functions, viability, and pathophysiology were assessed by MRI) and by histological analysis. At 24 hours post-CAL, left ventricular (LV) anterior wall motion was stunted to the same extent in control CAL and lenti-ACE2–treated CAL rats. However lenti-ACE2–treated CAL rats showed a 60% reduction in delayed contrast-enhanced LV volume after gadodiamide injection, indicating early ischemic protection of myocardium by ACE2. At 6 weeks after CAL, lenti-ACE2 rats demonstrated a complete rescue of cardiac output, a 41% rescue of ejection fraction, a 44% rescue in contractility, a 37% rescue in motion, and a 53% rescue in LV anterior (infracted) wall thinning compared with control CAL rats. No changes were observed in the LV posterior (noninfarcted) wall other than an 81% rescue in motion produced by ACE2 in CAL rats. Finally, infarct size measured by 2,3,5-triphenyl-tetrazolium chloride staining was not significantly different between the ligated groups. These observations demonstrate that cardiac overexpression of ACE2 exerts protective influence on the heart during myocardial infarction by preserving cardiac functions, LV wall motion and contractility, and by attenuating LV wall thinning.


Key words: ACE2 • heart disease • myocardial infarction • lentiviral vector • gene therapy